A Semi-Mechanistic Population Pharmacokinetic/Pharmacodynamic Model of Bortezomib in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

被引：0
|
作者：
Julie M. Janssen
T. P. C. Dorlo
D. Niewerth
A. J. Wilhelm
C. M. Zwaan
J. H. Beijnen
A. Attarbaschi
A. Baruchel
F. Fagioli
T. Klingebiel
B. De Moerloose
G. Palumbo
A. von Stackelberg
G. J. L. Kaspers
A. D. R. Huitema
机构：
[1] Netherlands Cancer Institute-Antoni van Leeuwenhoek,Department of Pharmacy and Pharmacology
[2] VU University Medical Center,Department of Pediatric Oncology/Hematology
[3] VU University Medical Center,Department of Clinical Pharmacology and Pharmacy
[4] Princess Maxima Center for Pediatric Oncology,Department of Pediatric Oncology/Hematology
[5] Erasmus-MC Sophia Children’s Hospital,Utrecht Institute for Pharmaceutical Sciences (UIPS)
[6] Utrecht University,Department of Pediatric Hematology and Oncology
[7] St. Anna Children’s Hospital,Department of Pediatrics and Adolescent Medicine
[8] Medical University Vienna,Department of Pediatric Hematology
[9] Hopital Saint Louis,Department of Pediatrics
[10] Università degli Studi di Torino,Department of Pediatrics
[11] University Hospital Frankfurt,Department of Pediatric Oncology/Hematology
[12] Ghent University Hospital,Department of Clinical Pharmacy, University Medical Center Utrecht
[13] Ospedale Pediatrico Bambino Gesù,undefined
[14] Charité Universitätsmedizin,undefined
[15] Utrecht University,undefined
[16] ITCC Consortium,undefined
来源：
Clinical Pharmacokinetics | 2020年 / 59卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：207 / 216
页数：9
相关论文
共 50 条
  • [1] A Semi-Mechanistic Population Pharmacokinetic/Pharmacodynamic Model of Bortezomib in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
    Janssen, Julie M.
    Dorlo, T. P. C.
    Niewerth, D.
    Wilhelm, A. J.
    Zwaan, C. M.
    Beijnen, J. H.
    Attarbaschi, A.
    Baruchel, A.
    Fagioli, F.
    Klingebiel, T.
    De Moerloose, B.
    Palumbo, G.
    Von Stackelberg, A.
    Kaspers, G. J. L.
    Huitema, A. D. R.
    CLINICAL PHARMACOKINETICS, 2020, 59 (02) : 207 - 216
  • [2] Use of Bortezomib in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia
    Bello, Adriana
    Cortez, Rossana
    Collazo, Maylu
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S269 - S270
  • [3] Application of Semi-Mechanistic Pharmacokinetic and Pharmacodynamic Model in Antimicrobial Resistance
    Mi, Kun
    Zhou, Kaixiang
    Sun, Lei
    Hou, Yixuan
    Ma, Wenjin
    Xu, Xiangyue
    Huo, Meixia
    Liu, Zhenli
    Huang, Lingli
    PHARMACEUTICS, 2022, 14 (02)
  • [4] Population Pharmacokinetic Model of Methotrexate in Brazilian Pediatric Patients with Acute Lymphoblastic Leukemia
    Pricilla de Oliveira Henz
    Amanda Valle Pinhatti
    Lauro José Gregianin
    Manoela Martins
    Marina Curra
    Bibiana Verlindo de Araújo
    Teresa Dalla Costa
    Pharmaceutical Research, 2023, 40 : 1777 - 1787
  • [5] Population Pharmacokinetic Model of Methotrexate in Brazilian Pediatric Patients with Acute Lymphoblastic Leukemia
    Henz, Pricilla de Oliveira
    Pinhatti, Amanda Valle
    Gregianin, Lauro Jose
    Martins, Manoela
    Curra, Marina
    de Araujo, Bibiana Verlindo
    Dalla Costa, Teresa
    PHARMACEUTICAL RESEARCH, 2023, 40 (07) : 1777 - 1787
  • [6] Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
    Deepa Bhojwani
    Richard Sposto
    Nirali N. Shah
    Vilmarie Rodriguez
    Constance Yuan
    Maryalice Stetler-Stevenson
    Maureen M. O’Brien
    Jennifer L. McNeer
    Amrana Quereshi
    Aurelie Cabannes
    Paul Schlegel
    Claudia Rossig
    Luciano Dalla-Pozza
    Keith August
    Sarah Alexander
    Jean-Pierre Bourquin
    Michel Zwaan
    Elizabeth A. Raetz
    Mignon L. Loh
    Susan R. Rheingold
    Leukemia, 2019, 33 : 884 - 892
  • [7] Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
    Bhojwani, Deepa
    Sposto, Richard
    Shah, Nirali N.
    Rodriguez, Vilmarie
    Yuan, Constance
    Stetler-Stevenson, Maryalice
    O'Brien, Maureen M.
    McNeer, Jennifer L.
    Quereshi, Amrana
    Cabannes, Aurelie
    Schlegel, Paul
    Rossig, Claudia
    Dalla-Pozza, Luciano
    August, Keith
    Alexander, Sarah
    Bourquin, Jean-Pierre
    Zwaan, Michel
    Raetz, Elizabeth A.
    Loh, Mignon L.
    Rheingold, Susan R.
    LEUKEMIA, 2019, 33 (04) : 884 - 892
  • [8] Bortezomib Combined Chemotherapy for Children with Relapsed/refractory Acute Lymphoblastic Leukemia
    Sakaguchi, Hirotoshi
    Maemura, Ryo
    Yamamori, Ayako
    Wakamatsu, Manabu
    Yoshida, Nao
    Kato, Koji
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S89 - S90
  • [9] Greater Efficacy and Potency of Obinutuzumab Compared with Rituximab in Chronic Lymphocytic Leukemia Patients Confirmed By a Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Model
    Kamisoglu, Kubra
    Phipps, Alex
    Jamois, Candice
    Buchheit, Vincent
    Meneses-Lorente, Georgina
    Fingerle-Rowson, Gunter
    Wagg, Jonathan
    Mager, Donald E.
    BLOOD, 2017, 130
  • [10] Semi-mechanistic autoinduction model of midazolam in critically ill patients: population pharmacokinetic analysis
    Aoyama, T.
    Hirata, K.
    Yamamoto, Y.
    Yokota, H.
    Hayashi, H.
    Aoyama, Y.
    Matsumoto, Y.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2016, 41 (04) : 392 - 398
12345